MeiraGTx Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
MeiraGTx Holdings plc (MGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 198.20 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-13
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was -6.44K shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 204.64K shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2021-09-30 was 22.11K shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2019-06-30 was 0.00 shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 0.00 shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2019 was 0.00 shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2018 was 0.00 shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2017 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -6.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 198.20K shares 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 204.64K shares 10-Q · filed 2026-05-14 | ||||
| 2021-09-30 | 22.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 98.03K shares 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 75.91K shares 10-Q · filed 2021-08-11 | ||||
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-10 | ||||
| 2019-12-31 | 0.00 shares 10-K · filed 2021-03-11 | 3.25M shares 10-K · filed 2020-03-11 | |||
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 0.00 shares 10-Q · filed 2019-08-07 | 0.00 shares derived: sum of 3 quarters · filed 2020-03-11 | 0.00 shares derived: sum of 4 quarters · filed 2020-03-11 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-14 | 0.00 shares derived: sum of 2 quarters · filed 2020-03-11 | 0.00 shares derived: sum of 3 quarters · filed 2020-03-11 | ||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | 0.00 shares derived: sum of 2 quarters · filed 2020-03-11 | 0.00 shares 10-K · filed 2020-03-11 | ||
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 0.00 shares 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | 0.00 shares 10-Q · filed 2018-08-08 | ||||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |